| This week's sponsor is INC Research. | |  | |
Top Stories Tuesday, October 4, 2016 Editas Medicine has nabbed former VP of rare disease clinical development Dr. Gerald Cox from Sanofi’s Genzyme to become its CMO. Wednesday, October 5, 2016 After handing over development of its experimental GI treatment MEDI2070 to Allergan this week, AstraZeneca has struck another licensing deal, this time with biotech Insmed and its respiratory candidate AZD7986. Wednesday, October 5, 2016 Cancer Research UK and London investment firm Syncona have joined forces to fund and launch a new neoantigen-focused lung cancer biotech. Wednesday, October 5, 2016 The Texas-based company has now made arrangements to pay its final obligations to Symphony Icon upon an FDA approval of telotristat ethyl to treat carcinoid syndrome. Wednesday, October 5, 2016 Bone Therapeutics has posted an interim look at data from a small Phase IIa trial of its allogeneic cell therapy in lumbar spinal fusion. The vertebral bodies fused in all 8 of the subjects to complete one year of follow up, putting Bone Therapeutics on a path it hopes will lead to a series of positive data readouts in 2017. Wednesday, October 5, 2016 Trinity Biotech has traveled a rough road with its point-of-care test for heart failure, and now, it’s reached the bitter end. The company is pulling back its FDA submission for the device after regulators voiced some concerns about the diagnostic. Wednesday, October 5, 2016 Researchers at Memorial Sloan Kettering have discovered something new about CAR-T immunotherapy: The cells can act as delivery vehicles for proteins that have the potential to treat lymphoma. | This week's sponsor is FierceBiotech. | |  | FierceBiotech Presents:
A Half Day Executive Summit
Hosted at the Royal Society of Medicine, London
R&D Challenges: A UK Perspective
Cocktail Reception to follow
27 October, 2016
Register Now! |
| | | Codexis has finished off the handover of its CodeEvolver protein engineering platform tech to Merck, gaining an $8 million payment from the U.S. Big Pharma. Release Catabasis Pharmaceuticals has made a brace of promotions as Andrew Nichols becomes its new CSO while Angelika Fretzen steps up to be the SVP of product development. Statement California biotech Regulus Therapeutics has also made a new appointment, that of Timothy Wright, who becomes its new chief R&D officer. Release NJ-based Immunomedics has priced an underwritten offering of 10 million shares of common stock and warrants as it looks to make $30 million. Statement | |
|
Resources Presented by: Covance The role of health economic data has never been more important. Presented by: Covance Leading manufacturers increasingly employ stakeholder research early in development to better identify the needs of patients and providers. Presented By: ISR Reports ISR’s Bioprocessing Market Trends and Outsourcing Dynamics: 2016-2021 report provides an overview of the current market dynamics for bioprocessing as well as an outlook on what the marketplace will look like in five years. Presented By: ISR Reports ISR’s CRO Quality Benchmarking – Phase II/III Service Providers (8th Edition) report provides a Consumer Reports-style analysis of Phase II/III CRO service quality from hundreds of users who rated 44 Phase II/III CROs across 26 critical dimensions of quality. Presented by: Patheon Can you avoid a risky trial-and-error approach to find the right path for your poorly soluble molecule by utilizing a CDMO? Download this complimentary Whitepaper to learn more! Presented by: Biotech Primer This 3-part webinar series is specifically geared toward the non-science professional who needs to better understand industry terminology, science, techniques and issues. Sponsored by: Veeva Systems Gartner research on short- and long-term strategies for IDMP compliance. | 
